For Massachusetts Eye and Ear Special Issue: Updates on Therapies for Multiple Sclerosis for the Ophthalmologist

References

• Simpson S Jr., Blizzard L, Otahal P, Van der Mei I, Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1132–1141. doi:10.1136/jnnp.2011.240432.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr., et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The optic neuritis study group. N Engl J Med. 1992;326(9):581–588. doi:10.1056/NEJM199202273260901.
   PubMed Web of Science ®Google Scholar
• Sa M, Ja F, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: A randomized clinical trial. JAMA Neurol. 2018;75(6):690–696. doi:10.1001/jamaneurol.2018.0024.
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology. 1993;43(4):655–661. doi:10.1212/wnl.43.4.655
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI study group and the IFNB multiple sclerosis study group. Neurology. 1993;43(4):662–667. doi:10.1212/wnl.43.4.662.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285–294. doi:10.1002/ana.410390304.
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904. doi:10.1056/NEJM200009283431301.
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–1582.
   PubMed Web of Science ®Google Scholar
• Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005;252(3):iii3–iii9. doi:10.1007/s00415-005-2010-6.
   PubMedGoogle Scholar
• Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015;21(8):1025–1035. doi:10.1177/1352458514557986.
   PubMed Web of Science ®Google Scholar
• Dr George C Ebers, PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group.Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–1504.
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496–1506. doi:10.1212/01.wnl.0000034080.43681.da.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Schrempf W. Glatiramer acetate: mechanisms of action in multiple sclerosis. Int Rev Neurobiol. 2007;79:537–570. doi:10.1016/S0074-7742(07)79024-4.
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group. Neurology. 1995;45(7):1268–1276. doi:10.1212/wnl.45.7.1268.
   PubMed Web of Science ®Google Scholar
• Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158(5):1173–1182. doi:10.1111/j.1476-5381.2009.00451.x.
   PubMed Web of Science ®Google Scholar
• Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther. 2007;323(2):626–635. doi:10.1124/jpet.107.123927.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi:10.1056/NEJMoa0909494.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi:10.1056/NEJMoa0907839.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–674. doi:10.1007/s40265-014-0212-x.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256. doi:10.1016/S1474-4422(13)70308-9.
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977–986. doi:10.1016/S1474-4422(14)70191-7.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20(6):705–716. doi:10.1177/1352458513507821.
   PubMed Web of Science ®Google Scholar
• Miller AE. Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience. Ther Adv Neurol Disord. 2017;10(12):381–396. doi:10.1177/1756285617722500.
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014;3(2):133–138. doi:10.1007/s40120-014-0020-y.
   PubMedGoogle Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107. doi:10.1056/NEJMoa1114287.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097. doi:10.1056/NEJMoa1206328.
   PubMed Web of Science ®Google Scholar
• Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8(1):20–30. doi:10.1177/1756285614564152.
   PubMed Web of Science ®Google Scholar
• Kawamoto E, Nakahashi S, Okamoto T, Imai H, Shimaoka M. Anti-integrin therapy for multiple sclerosis. Autoimmune Dis. 2012;2012:357101.
   PubMedGoogle Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. doi:10.1056/NEJMoa044397.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–260. doi:10.1016/S1474-4422(09)70021-3.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Kappos L. PML risk and natalizumab: the elephant in the room. Lancet Neurol. 2017;16(11):864–865. doi:10.1016/S1474-4422(17)30335-6.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–368. doi:10.1056/NEJMoa051586.
   PubMed Web of Science ®Google Scholar
• Schwab N, Ulzheimer JC, Fox RJ, et al. Fatal PML associated with efalizumab therapy: insights into integrin alphaLbeta2 in JC virus control. Neurology. 2012;78(7):458–467. discussion 465. doi:10.1212/WNL.0b013e3182478d4b.
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol Res. 2006;28(3):236–244. doi:10.1179/016164106X98099.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688. doi:10.1056/NEJMoa0706383.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460–471. doi:10.1002/ana.21867.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016;87(20):2074–2081. doi:10.1212/WNL.0000000000003331.
   PubMed Web of Science ®Google Scholar
• Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79(6):950–958. doi:10.1002/ana.24651.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787. doi:10.1016/S0140-6736(11)61649-8.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234. doi:10.1056/NEJMoa1601277.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220. doi:10.1056/NEJMoa1606468.
   PubMed Web of Science ®Google Scholar
• Investigators CT, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–1801. doi:10.1056/NEJMoa0802670.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338–348. doi:10.1016/S1474-4422(11)70020-5.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi:10.1016/S0140-6736(12)61768-1.
   PubMed Web of Science ®Google Scholar
• Moss HE. Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown. Eye Brain. 2017;9:13–21. doi:10.2147/EB.S140481.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14(4):874–887. doi:10.1007/s13311-017-0573-4.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426. doi:10.1056/NEJMoa0902533.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–267. doi:10.1016/S1474-4422(14)70005-5.
   PubMed Web of Science ®Google Scholar
• Nj S, Pasquini M, Sc R, et al. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776–2796. doi:10.1093/brain/awx154.
   PubMedGoogle Scholar
• Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. doi:10.1016/S0140-6736(18)30475-6.
   PubMed Web of Science ®Google Scholar
• Cadavid D, Balcer L, Galetta S, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189–199. doi:10.1016/S1474-4422(16)30377-5.
   PubMed Web of Science ®Google Scholar
• Tourbah A, Lebrun-Frenay C, Edan G, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Mult Scler. 2016;22(13):1719–1731. doi:10.1177/1352458516667568.
   PubMed Web of Science ®Google Scholar
• Tourbah A, Gout O, Vighetto A, et al. MD1003 (high-dose pharmaceutical-grade biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study. CNS Drugs. 2018;32(7):661–672. doi:10.1007/s40263-018-0528-2.
   PubMed Web of Science ®Google Scholar
• Granella F Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Oct 2017.
   Google Scholar
• Villoslada P. Neuroprotective therapies for multiple sclerosis and other demyelinating diseases. Mult Scler DemyelinatingDisord. 2016;1(1):1.doi:10.1186/s40893-016-0004-0.
   Google Scholar